Get the Stockscreener App
25.28
1.12%
0.28
Artivion Inc stock is traded at $25.28, with a volume of 370.00K.
It is up +1.12% in the last 24 hours and up +14.75% over the past month.
Artivion Inc offers cardiac and vascular surgeons a suite of aortic-centric solutions. The company's products include Aortic Heart Valve, Mitral Heart Valve, Aortic Allograft, Pulmonary Human Heart Valve, Pulmonary Patch, and Surgical Adhesive among others. The company's has two reportable segments: Medical Devices and Preservation Services. The Medical Devices segment includes revenues from sales of aortic stent grafts, surgical sealants, On-X products, and other product revenues. The Preservation Services segment includes services revenues from the preservation of cardiac and vascular implantable human tissues. Company operates in North America, EMEA. LATAM, APAC. Maximum revenue is from North America.
See More
Previous Close:
$25.00
Open:
$25.25
24h Volume:
370.00K
Relative Volume:
0.49
Market Cap:
$1.23B
Revenue:
$458.69M
Net Income/Loss:
$11.68M
P/E Ratio:
105.25
EPS:
0.2402
Net Cash Flow:
$14.58M
1W Performance:
+0.88%
1M Performance:
+14.75%
6M Performance:
-41.24%
1Y Performance:
-18.58%
1-Day Range:
$24.82
$25.59
1-Week Range:
$24.55
$25.68
52-Week Range:
$19.16
$48.25
Artivion Inc Stock (AORT) Company Profile
Name
Artivion Inc
Sector
Industry
Phone
(770) 419-3355
Address
1655 ROBERTS BOULEVARD N W, KENNESAW
Compare AORT vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
AORT
Artivion Inc
|
25.28 | 1.23B | 458.69M | 11.68M | 14.58M | 0.2402 |
ABT
Abbott Laboratories
|
103.06 | 179.51B | 46.59B | 5.41B | 7.38B | 3.0938 |
SYK
Stryker Corp
|
330.25 | 126.60B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
83.21 | 106.51B | 36.36B | 4.84B | 5.43B | 3.7261 |
BSX
Boston Scientific Corp
|
44.25 | 65.77B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
82.63 | 47.58B | 6.30B | 1.07B | 1.09B | 1.8406 |
Artivion Inc Stock (AORT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Upgrade | Ladenburg Thalmann | Neutral → Buy |
| Aug-13-25 | Downgrade | Ladenburg Thalmann | Buy → Neutral |
| Jun-17-25 | Initiated | Canaccord Genuity | Buy |
| Oct-23-24 | Initiated | JMP Securities | Mkt Outperform |
| Sep-27-22 | Reiterated | Lake Street | Buy |
| Aug-08-22 | Initiated | Lake Street | Buy |
| Mar-03-22 | Initiated | Stifel | Buy |
View All
Artivion Inc Stock (AORT) Latest News
Artivion, Inc. (AORT) stock price, news, quote and history - Yahoo Finance UK
Artivion schedules Q2 results webcast for Aug. 6 at 4:30 p.m. - Stock Titan
Artivion Announces Release Date and Teleconference Call Details for Second Quarter 2026 Financial Results - TradingView
Artivion (AORT) Grew in Q1, but AMDS Timing and Lower 2026 Targets Still Softened the Story - AlphaStreet
Below Expected Sales for AMDS Hurt Artivion (AORT) in Q2 - Yahoo Finance
Citizens reiterates Artivion stock rating citing FDA approval benefits - Investing.com
Needham reiterates Artivion stock rating on product cycle outlook - Investing.com
Needham reiterates Artivion stock rating on product cycle outlook By Investing.com - Investing.com Canada
Artivion (AORT) Corporate presentation Summary - Quartr
Artivion, Inc. (AORT) Stock Live Price, Chart & News - CoinCodex
Artivion, Inc. (AORT) Stock Forecast & Price Prediction 2026–2030 - CoinCodex
AORT Q1 2026 Earnings: EPS Misses Estimates, Stock Edges LowerDividend Growth Analysis - Bölüm Sonu Canavarı
Artivion (AORT) Stifel 2025 Healthcare Conference Summary - Quartr
Artivion (AORT) Is Up 10.1% After Full FDA PMA Approval for AMDS Aortic Device - simplywall.st
What Boosted Artivion (NYSE:AORT) Following FDA PMA Approval? - Kalkine Media
Artivion seeks to tap $150 million US market opportunity with FDA approval - MSN
Artivion stock gets FDA approval for NEXUS stent graft system By Investing.com - Investing.com India
Artivion (AORT) Stock Forum and Discussion - Moomoo
AORTArtivion Inc Options - Finviz
Artivion raises 2025 revenue guidance to $435M–$443M as On-X and stent grafts drive double-digit growth - MSN
Artivion Secures FDA Approval for AMDS Hybrid Prosthesis Device - Yahoo Finance
Artivion: PMA Approval Supports Accelerating Growth And Margin Expansion (NYSE:AORT) - Seeking Alpha
Artivion stock rises after FDA approves AMDS device - Investing.com
Enterprise value to revenue forward of Artivion, Inc. – SWB:CYL - TradingView
Canaccord reiterates Artivion stock rating on FDA approval By Investing.com - Investing.com South Africa
Artivion (AORT) Secures FDA Approval for AMDS Hybrid Prosthesis - GuruFocus
Artivion Seeks To Tap $150 Million US Market Opportunity With FDA Approval - Benzinga
Why Artivion (AORT) Is Up 17.3% After Full FDA PMA Approval for AMDS Hybrid Prosthesis - simplywall.st
Artivion receives FDA PMA approval for AMDS Hybrid Prosthesis in aortic dissections - grafa.com
Canaccord reiterates Artivion stock rating on FDA approval - Investing.com
Artivion Shares Rise After FDA Approves AMDS Aortic Device - TradingPedia
Artivion Wins FDA Nod for AMDS Hybrid Prosthesis - Medical Product Outsourcing
Artivion stock rises after FDA approves AMDS device By Investing.com - Investing.com Canada
Artivion, Inc.(NYSE: AORT) dropped from Russell Microcap Value Benchmark Index - marketscreener.com
Artivion's Hybrid Prosthesis Device Gets FDA Premarket Approval; Shares Up Pre-Bell - Moomoo
Artivion receives FDA approval for aortic dissection device By Investing.com - Investing.com South Africa
Artivion receives FDA approval for aortic dissection device - Investing.com
Artivion, Inc.(NYSE: AORT) dropped from Russell 2000 Value Benchmark - marketscreener.com
Artivion Announces U.S. FDA Approval of the AMDS Hybrid Prosthesis - PR Newswire
Artivion, Inc.(NYSE: AORT) dropped from Russell 3000E Index - marketscreener.com
Artivion, Inc.(NYSE: AORT) dropped from Russell Microcap Index - marketscreener.com
Artivion, Inc.(NYSE: AORT) dropped from Russell 3000E Growth Benchmark - marketscreener.com
Artivion, Inc.(NYSE: AORT) dropped from Russell Microcap Growth Benchmark Index - marketscreener.com
Price to earnings forward of Artivion, Inc. – NYSE:AORT - TradingView
Enterprise value to EBITDA forward of Artivion, Inc. – SWB:CYL - TradingView
Price to sales forward of Artivion, Inc. – SWB:CYL - TradingView
Artivion, Inc.(NYSE: AORT) dropped from Russell 2000 Value-Defensive Index - marketscreener.com
Artivion, Inc. Actuals & Estimates (NYSE:AORT) - TradingView
AORT Forecast — Price Target — Prediction for 2027 - TradingView
Artivion (AORT) Q1 2026 Earnings: EPS Misses Estimates but Stock Rises 6.53%Consensus Beat Rate - DonanımHaber
Artivion Inc (AORT) Valuation: PE, PB & Fair Value Analysis - TradingKey
Artivion Inc Stock (AORT) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.90%
2.27%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):